GeneralConnection.com ➔ Dictionary
Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
Achondroplasia Awareness – sponsored content - MyWabashValley.com
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
Next generation approaches to achondroplasia care - Drug Discovery News
Homozygous Achondroplasia With Long-Term Survival: Growth Patterns, Medical Interventions, and Practice Implications - Wiley Online Library
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Answers
Once-Weekly Navepegritide Safe and Efficacious for Achondroplasia, With Carlos Bacino, MD - HCPLive
Pregnancy and Delivery in a Woman With Achondroplasia: A Multidisciplinary Management Approach - Cureus
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
'New achondroplasia drugs may increase height by up to 20 cm' - koreabiomed.com
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
New treatment gives hope to children with achondroplasia - Loma Linda University
Oral medication boosts annualized height velocity for children with achondroplasia - Healio
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
BridgeBio drug for genetic cause of dwarfism succeeds in key study - statnews.com
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord Pharma
FDA approves dwarfism drug - Nature
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCPLive
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward - BioSpace
FDA Approves Navepegritide for Children With Achondroplasia - Pharmacy Times
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
COACH trial: hGH accelerates CNP benefits in achondroplasia - The Clinical Trial Vanguard
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
Navepegritide Shows 5.84 cm/year Growth Velocity in Achondroplasia Trial - The Clinical Trial Vanguard
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia - Contemporary Pediatrics
FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older - HCPLive
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children - BioSpace
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting - PR Newswire
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
Ascendis Pharma Receives FDA Approval for YUVIWEL®, First Once-Weekly Treatment for Achondroplasia in Children - Quiver Quantitative
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - GlobeNewswire
First-of-its-kind trial boosts growth in children with rare disorders - Children's National
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
Figure 5. [Achondroplasia- Small rounded iliac bones,...]. - Endotext - National Institutes of Health (.gov)
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication - BioSpace
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
Camp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions - BioMarin Pharmaceutical
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® - GlobeNewswire
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
Abbisko Therapeutics' FGFR2/3 inhibitor ABSK061 receives FDA IND clearance for achondroplasia in children - Select Science
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
Here we grow: chondrocytes’ behavior reveals novel targets for bone growth disorders - Asia Research News |
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
Jake Birecki Makes Space for Passion, Purpose and Play - BioMarin Pharmaceutical
Arvada boy with dwarfism thrives at school thanks to doctor who goes the extra mile - KUSA.com
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
Ascendis reports arm span, spinal improvements in achondroplasia trial - Investing.com
BioMarin moves to expand Voxzogo into hypochondroplasia with pivotal win - FirstWord Pharma
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com
BioMarin’s Vosoritide Shows 2.33 cm/yr Growth Gain in Hypochondroplasia Trial - The Clinical Trial Vanguard
Abbisko Therapeutics Secures FDA IND Clearance For ABSK061 In Achondroplasia - BioPharma APAC
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Yahoo Finance
BioMarin notches win in study that could expand use of top-selling medicine - BioPharma Dive
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older - BioSpace
BridgeBio data for dwarfism drug sets up showdown with BioMarin's Voxzogo - FirstWord Pharma
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - Yahoo Finance
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com
Inside pharma’s race to deliver new treatments for dwarfism - Pharma Voice
New Data from Week 52 of the Ongoing COACH Trial Showed - GlobeNewswire
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid - Fierce Pharma
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld News
Ascendis wins FDA approval of dwarfism drug - BioPharma Dive
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data - Citeline News & Insights
FDA delays decision on Ascendis' dwarfism prospect by 3 months - Fierce Biotech
Assessing Abbisko Cayman (SEHK:2256) Valuation After FDA Clears ABSK061 IND For Pediatric Achondroplasia - Yahoo Finance
BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com
Doctor helps Colorado boy with dwarfism thrive at school - KUSA.com
Jake Birecki: Making Space of Strength, Sports and Self - BioMarin Pharmaceutical
Ascendis scores FDA approval for weekly dwarfism drug - pharmaphorum
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Yahoo Finance
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Yahoo Finance
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Yahoo Finance
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia - Indian Pharma Post
Six-year study finds bone health maintained in children on VOXZOGO - Stock Titan
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
Human genetic disease - Autosomal Dominant, Inheritance, Genes - Britannica
Dwarfism drug gets FDA accelerated approval for Ascendis - BioWorld News
Once Weekly CNP Therapy Shows Promise In Advancing Achondroplasia Treatment - BioSpectrum Asia
Ascendis' weekly achondroplasia drug sustained growth gains for 2 years - Stock Titan
FDA Approves Navepegritide for Achondroplasia in Children - Medical Dialogues
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
achondoplasia,   achondeoplasia,   achondrplasia,   avhondroplasia,   achonsroplasia,   achodroplasia,   achondrolpasia,   achondroplssia,   achondrroplasia,   acchondroplasia,   achondroplasua,   achondorplasia,   achhondroplasia,   achonddroplasia,   achondroplsaia,   acohndroplasia,   achonroplasia,   achobdroplasia,   achpndroplasia,   acondroplasia,   achondroplaia,   achondroplaisa,   achondroplassia,   achondroplaaia,   achonndroplasia,   acgondroplasia,   achondrpolasia,   achondropplasia,   schondroplasia,   chondroplasia,   achondrolasia,   axhondroplasia,   achonfroplasia,   achondroplsia,   aachondroplasia,   achondrpplasia,   achondroplasoa,   achondroolasia,   achonrdoplasia,   achondroplasiaa,   achondroplasiia,   achondropkasia,   achndroplasia,   achondrop;asia,   achondroplasis,   cahondroplasia,   achondropalsia,   ahcondroplasia,   achondroplasa,   achodnroplasia,   achondriplasia,   achondropladia,   achondrooplasia,   achondropllasia,   achnodroplasia,   achondroplaasia,   acjondroplasia,   achondro[lasia,   achomdroplasia,   achondropasia,   achondtoplasia,   achindroplasia,   ahondroplasia,   achondroplasai,   achondroplasi,   achoondroplasia
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z